I recently stumbled upon a presentation with the heading “One Billion Doses of Breakthrough “Super Vaccine” Slated for Production!”
In the presentation, former Fox News anchor Suzanne Sena and Michael Robinson talk about a coronavirus “super vaccine” that will revolutionize the healthcare sector.
He believes that one company that will produce it will be a lucrative investment for people who start racking up shares as soon as they can.
In this review, I take a closer look at the main talking points of the pitch before I share my thoughts on the viability of the investment.
I also reveal the name of the Biotech Stock.
Before I start…
If you’re tired of scams and want a real solution for making money online check out my no.1 recommendation.
It’s helped me earn over $300,000 in the last 12 months alone:
Go here to see my no.1 recommendation for making money online
(This is a 100% free training)
Breakthrough “Super Vaccine” Review
Introduction to Breakthrough “Super Vaccine”
The presentation by Michael Robinson concerns a “Super Vaccine” for COVID-19 that he claims has already received FDA approval for its Phase 1 testing.
He says that it has successfully triggered an immune response in humans against the coronavirus, which is good news for everyone considering the widespread impact of the virus.
The company that he thinks will be the most profitable investment going forward records $60 million in sales per year, on average, but he says that once it starts producing the COVID-19 vaccine, its sales may surge by 58,300%.
While this is a win for humanity, Robinson looks at it from an investor’s point of view; he sees the potential for the small pharmaceutical company to increase its stock value tremendously due to the improved sales.
He wants his followers to get in on it as soon as they can, preferably before it (potentially) starts producing the vaccine and soars in value.
RECOMMENDED: Go here to see my no.1 recommendation for making money online
What is this “Super Vaccine” Robinson is talking about?
Michael Robinson says that he is referring to it as “Super Vaccine” because it is not just going to achieve one objective, it will achieve three:
- It will eradicate the COVID-19 pandemic as well as other pandemics before they start.
- Its platform can be customized to help fight diabetes, cancer, heart disease, and other conditions
- It will revolutionize the $3.2 trillion healthcare industry.
He mentions that unlike other virus vaccines that take time to develop and administer, this “super vaccine” is pioneering the way vaccines will be administered; instead of injecting the virus into the body, they will inject an mRNA that will instruct the on DNA how to tackle the virus.
It will be a more effective way to administer the vaccine and can potentially be replicated with other viruses.
That’s why Robinson says it will be used during other pandemics and compares its impact with the invention of antibiotics and penicillin.
RECOMMENDED: Go here to see my no.1 recommendation for making money online
Why is Michael Robinson confident in this biotech?
There are a few reasons Michael Robinson is touting this company. The three main ones are:
First, it conducted Phase 1 human trials in record time. Like other biotech companies, it is a beneficiary of the $10 billion public-private partnership called Operation Warp Speed whose main aim is to accelerate the development of COVID-19 vaccines and therapies. However, Robinson says its vaccine is so good, it received Phase 1 human trial approval from the FDA in the shortest duration.
Second, Dr. Moncef Slaoui, whom President Trump appointed to lead the US initiative to develop coronavirus vaccine and therapies, held over $10 million worth of its stock options. Since Dr. Slaoui is an experienced vaccine developer, Robinson argues that him having trusted the company enough to invest in it means it has bright prospects.
Third, it has signed a contract to supply one billion doses for 12 months and 10 billion doses for the next 10 years.
Other reasons are:
- It has over 100 patents protecting its proprietary technology.
- Big pharmaceutical companies and the DoD want to partner with it to bring the vaccine to market.
RECOMMENDED: Go here to see my no.1 recommendation for making money online
Who is behind the Breakthrough “Super Vaccine” presentation?
Although Suzanne Sena, a former Fox News anchor, hosts the presentation, the focus is on Michael Robinson.
Michael is the director of technology and venture capital research at Money Morning, which is analogous to Money Map Press. He edits Nova X Report and Radical Technology Profits.
He is one of the most experienced investment analysts in the newsletter world because he has over 35 years of experience in Silicon Valley. He has served as a consultant for multiple venture capital firms that look for tech startups to invest in, leveraging his experience to help them find the best opportunities.
Besides working for the venture capitalists, he has also been a senior advisor to 12 startups that were involved in big medical and technological breakthroughs.
RECOMMENDED: Go here to see my no.1 recommendation for making money online
How to invest in the Breakthrough “Super Vaccine”
Michael Robinson wants you to invest in the “super vaccine” as soon as you can. Although he focuses on the biotech company developing the vaccine, there are other avenues of investment he wants you to explore.
In addition to the biotech company, he also wants you to invest in the pharmaceutical company that will manufacture the vaccine and the company leading the testing.
To learn more about those investments, you have to subscribe to his new investment advisory service, Bio-Technology Profit Alliance.
In addition to those investments, he shares a few other bonus investments through the following dossiers:
- Affordable Insulin for 7.5M Americans
- Disrupting the $4 Billion Orthodontic Market.
Subscription Fee
The annual subscription fee for Bio-Technology Profit Alliance is $1,950
Refund Policy
You can ask for a refund if you fail to receive at least 50 opportunities to grow your investment during the duration of your subscription.
RECOMMENDED: Go here to see my no.1 recommendation for making money online
What is the name of the company behind the Breakthrough “Super Vaccine”?
The company that Michael touts in the presentation is Moderna, MRNA (NASDAQ).
Tracing it wasn’t tough considering that Dr. Slaoui’s appointment by President Trump got people digging up his credentials and holdings. His involvement with Moderna was hard to miss, and, in fact, sparked a bit of controversy.
He had a $10 million investment in Moderna stock options just as Robinson mentions in the video.
To weather the storm, Dr. Slaoui divested himself of the holdings and pledged to donate the profit he had made since his appointment to cancer research.
RECOMMENDED: Go here to see my no.1 recommendation for making money online
Is Breakthrough “Super Vaccine” Legit?
Michael Robinson’s Breakthrough “Super Vaccine” presentation is legit.
The company he touts in the presentation, Moderna (MRNA), looks to be one of the leading biotech companies in developing a vaccine for coronavirus. Although it has hit a few bumps along the way, it has managed to keep up with the leading pack of companies expected to bring the vaccine to market.
Other analysts have been tipping it to do well in the next 12 months, which means Robinson is not off the mark with this one.
Pros of Breakthrough “Super Vaccine”
FDA granted phase 1 approval for the vaccine “in record time,” and that is a good indicator that the vaccine may clear the remainder of its trials.
Cons of Breakthrough “Super Vaccine”
The company has only passed Phase 1 of testing. It still has three extra phases of human clinical trials to go through and there are no guarantees that it will clear all of them.
RECOMMENDED: Go here to see my no.1 recommendation for making money online
Breakthrough “Super Vaccine” Verdict
As we have established, the company behind the “Super Vaccine” that Michael Robinson touts is Moderna (MRNA). It is one of the companies leading the development of a COVID-19 vaccine and appears to be well-positioned to grab a slice of the market share once the vaccine hits the market.
I also think there is still a long way to go for the vaccine to be mass-produced because clinical trials take time.
Therefore, if you invest in Moderna, you have to remain patient and hope that it sails through the remaining clinical trials smoothly while maintaining a lead over its competitors to yield the returns Michael is alluding to.
Before you leave
If you’re tired of scams and want a real solution for making money online check out my no.1 recommendation.
It’s helped me earn over $300,000 in the last 12 months alone:
Go here to see my no.1 recommendation for making money online
(This is a 100% free training)
David Fortune has been the editor NoBSIMReviews.com since 2019. He is an expert at writing content on stock advisory services, side hustles, reviewing online business opportunities and many more topics. You can learn more about David on our about us page.